CATX – perspective therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Perspective Therapeutics, Inc. (NYSE: CATX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $11.00 price target on the stock, down previously from $20.00.
Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-a-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium
Perspective Therapeutics to Discuss Data on [212Pb]VMT-a-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results
Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2024 Financial Results
Form 8-K Perspective Therapeutics For: Nov 21
Form 8-K Perspective Therapeutics For: Nov 15
Form SC 13G Perspective Therapeutics Filed by: Avidity Partners Management LP
Form SC 13G/A Perspective Therapeutics Filed by: COMMODORE CAPITAL LP
Form SC 13G Perspective Therapeutics Filed by: JANUS HENDERSON GROUP PLC
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.